VIPoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Madhu Sigdel (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (14 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VIPoma}} | {{VIPoma}} | ||
{{CMG}}{{AE}}{{MSI}}{{PSD}} | {{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}} | ||
==Overview== | ==Overview== | ||
Initial treatment in patient with VIPoma is prompt replacement of fluid and correction of electrolyte imbalance and acid-base disturbance. | Initial treatment in [[patient]] with VIPoma is [[prompt]] [[Fluid replacement therapy|replacement of fluid]] and correction of [[electrolyte imbalance]] and [[Acid-base disturbances|acid-base disturbance]]. [[Sandostatin|Somatostatin]] analogues like short acting [[octreotide]] is useful for controlling [[diarrhea]] by blocking the release of [[Vasoactive intestinal peptide|VIP]]. [[Octreotide]] is later replaced by longer acting depot preparation of [[somatostatin]] analogues like [[sandostatin]] or [[lanreotide]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
= | ===Initial treatment=== | ||
*Initial treatment in patient with VIPoma is prompt replacement of fluid and electrolyte losses. The IV fluid of choice is isotonic normal saline with added | *Initial treatment in patient with VIPoma is [[prompt]] [[Fluid replacement therapy|replacement of fluid]] and [[Electrolyte disturbance|electrolyte losses]]. | ||
*The [[IV fluids|IV fluid]] of choice is [[isotonic]] [[normal saline]] with added [[potassium]] and [[bicarbonate]] as necessary. | |||
=Medical management of advanced local or metastatic disease= | === Medical management === | ||
*There has been limited use of chemotherapy in patients with VIPoma. However, streptozocin based chemotherapy is considered best. | *[[Sandostatin|Somatostatin]] analogues like short acting [[octreotide]] is useful for controlling [[diarrhea]] by blocking the release of [[Vasoactive intestinal peptide|VIP]].<ref name="pmid2545444">{{cite journal| author=O'Dorisio TM, Mekhjian HS, Gaginella TS| title=Medical therapy of VIPomas. | journal=Endocrinol Metab Clin North Am | year= 1989 | volume= 18 | issue= 2 | pages= 545-56 | pmid=2545444 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2545444 }}</ref> | ||
*Most successful and favourable combination regimen of chemotherapy is | *[[Octreotide]] is later replaced by longer acting depot preparation of [[somatostatin]] analogues like [[sandostatin]] or [[lanreotide]]. | ||
* | *[[Steroids]] are used in [[diarrhea]] of VIPoma [[refractory]] to [[somatostatin]]. | ||
*Other molecular targeted therapy undergoing research for treatment are Everolimus (mTOR inhibitor) and Bevacizumab ( anti-VEGF monoclonal antibody) | *'''<u>Initial Management</u>''' | ||
** '''Preferred regimen (1)''' : [[Octreotide]] 50-100mcg q8h initially | |||
* '''<u>Maintenance dosage</u>''' | |||
**'''Preferred regimen (1)''': [[Sandostatin]] 20 mg IM every 4 weeks [[Lanreotide]] (120mg [[Subcutaneous|subcutaneously]] every 4 weeks). '''(OR)''' | |||
** '''Preferred regimen (2)''': [[Lanreotide]] 120mg [[Subcutaneous|subcutaneously]] every 4 weeks. | |||
* '''<u>Refractory cases</u>''' | |||
** '''Preferred regimen (1)''': [[Prednisone]] 60 mg IM q24 for 1 week. | |||
** '''Preferred regimen (2)''': [[Sunitinib]] 37.5 mg PO q24h. | |||
===Medical management of advanced local or metastatic disease=== | |||
*There has been limited use of [[chemotherapy]] in [[patients]] with VIPoma. However, [[streptozocin]] based [[chemotherapy]] is considered best in the management of advanced [[local]] or [[metastatic]] [[disease]].<ref name="pmid1310159">{{cite journal| author=Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D| title=Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. | journal=N Engl J Med | year= 1992 | volume= 326 | issue= 8 | pages= 519-23 | pmid=1310159 | doi=10.1056/NEJM199202203260804 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1310159 }}</ref><ref name="pmid15570077">{{cite journal| author=Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R et al.| title=Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 23 | pages= 4762-71 | pmid=15570077 | doi=10.1200/JCO.2004.04.024 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15570077 }}</ref><ref name="pmid27461388">{{cite journal| author=Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A| title=Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. | journal=Endocr Relat Cancer | year= 2016 | volume= 23 | issue= 9 | pages= R423-36 | pmid=27461388 | doi=10.1530/ERC-16-0200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27461388 }}</ref><ref name="pmid23840053">{{cite journal| author=Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN| title=Current understanding of the molecular biology of pancreatic neuroendocrine tumors. | journal=J Natl Cancer Inst | year= 2013 | volume= 105 | issue= 14 | pages= 1005-17 | pmid=23840053 | doi=10.1093/jnci/djt135 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23840053 }}</ref> | |||
*Most successful and favourable combination regimen of [[chemotherapy]] is [[streptozocin]] with [[Doxorubicin hydrochloride|doxorubicin]] together with [[somatostatin]] analogues. | |||
*[[Fluorouracil|5-FU]] can be used as alternative to [[Doxorubicin hydrochloride|doxorubicin]] in [[patients]] with who have [[contraindications]] to [[Doxorubicin|doxorubucin]]. | |||
*[[Sunitinib]] (37.5 mg [[oral]] once a day) a tyrosin kinase [[inhibitor]] has some evidence of [[symptomatic]] and [[biochemical]] control in [[somatostatin]] analogue resistant VIPoma. | |||
*Other [[molecular]] [[targeted therapy]] undergoing [[research]] for treatment are [[Everolimus]] ([[mTOR]] [[inhibitor]]) and [[Bevacizumab]] ( anti-[[Vascular endothelial growth factor|VEGF]] [[monoclonal antibody]]). | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma medical therapy On the Web |
|
American Roentgen Ray Society Images of VIPoma medical therapy |
|
Risk calculators and risk factors for VIPoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
Initial treatment in patient with VIPoma is prompt replacement of fluid and correction of electrolyte imbalance and acid-base disturbance. Somatostatin analogues like short acting octreotide is useful for controlling diarrhea by blocking the release of VIP. Octreotide is later replaced by longer acting depot preparation of somatostatin analogues like sandostatin or lanreotide.
Medical Therapy
Initial treatment
- Initial treatment in patient with VIPoma is prompt replacement of fluid and electrolyte losses.
- The IV fluid of choice is isotonic normal saline with added potassium and bicarbonate as necessary.
Medical management
- Somatostatin analogues like short acting octreotide is useful for controlling diarrhea by blocking the release of VIP.[1]
- Octreotide is later replaced by longer acting depot preparation of somatostatin analogues like sandostatin or lanreotide.
- Steroids are used in diarrhea of VIPoma refractory to somatostatin.
- Initial Management
- Preferred regimen (1) : Octreotide 50-100mcg q8h initially
- Maintenance dosage
- Preferred regimen (1): Sandostatin 20 mg IM every 4 weeks Lanreotide (120mg subcutaneously every 4 weeks). (OR)
- Preferred regimen (2): Lanreotide 120mg subcutaneously every 4 weeks.
- Refractory cases
- Preferred regimen (1): Prednisone 60 mg IM q24 for 1 week.
- Preferred regimen (2): Sunitinib 37.5 mg PO q24h.
Medical management of advanced local or metastatic disease
- There has been limited use of chemotherapy in patients with VIPoma. However, streptozocin based chemotherapy is considered best in the management of advanced local or metastatic disease.[2][3][4][5]
- Most successful and favourable combination regimen of chemotherapy is streptozocin with doxorubicin together with somatostatin analogues.
- 5-FU can be used as alternative to doxorubicin in patients with who have contraindications to doxorubucin.
- Sunitinib (37.5 mg oral once a day) a tyrosin kinase inhibitor has some evidence of symptomatic and biochemical control in somatostatin analogue resistant VIPoma.
- Other molecular targeted therapy undergoing research for treatment are Everolimus (mTOR inhibitor) and Bevacizumab ( anti-VEGF monoclonal antibody).
References
- ↑ O'Dorisio TM, Mekhjian HS, Gaginella TS (1989). "Medical therapy of VIPomas". Endocrinol Metab Clin North Am. 18 (2): 545–56. PMID 2545444.
- ↑ Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992). "Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma". N Engl J Med. 326 (8): 519–23. doi:10.1056/NEJM199202203260804. PMID 1310159.
- ↑ Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R; et al. (2004). "Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas". J Clin Oncol. 22 (23): 4762–71. doi:10.1200/JCO.2004.04.024. PMID 15570077.
- ↑ Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A (2016). "Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours". Endocr Relat Cancer. 23 (9): R423–36. doi:10.1530/ERC-16-0200. PMID 27461388.
- ↑ Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN (2013). "Current understanding of the molecular biology of pancreatic neuroendocrine tumors". J Natl Cancer Inst. 105 (14): 1005–17. doi:10.1093/jnci/djt135. PMID 23840053.